Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

• Published in: Molecular imaging and biology Vol. 17; no. 4; pp. 565 - 574
• Main Authors: Szabo, Zsolt, Mena, Esther, Rowe, Steven P., Plyku, Donika, Nidal, Rosa, Eisenberger, Mario A., Antonarakis, Emmanuel S., Fan, Hong, Dannals, Robert F., Chen, Ying, Mease, Ronnie C., Vranesic, Melin, Bhatnagar, Akrita, Sgouros, George, Cho, Steve Y., Pomper, Martin G.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.08.2015; Springer Nature B.V
• Subjects: Aged; Antigens, Surface - metabolism; Feasibility Studies; Glutamate Carboxypeptidase II - metabolism; Humans; Imaging; Lysine - adverse effects; Lysine - analogs & derivatives; Lysine - pharmacokinetics; Lysine - therapeutic use; Male; Medicine; Medicine & Public Health; Middle Aged; Positron-Emission Tomography - methods; Prostate - metabolism; Prostatic Neoplasms - diagnostic imaging; Prostatic Neoplasms - metabolism; Radiology; Radiometry; Research Article; Tissue Distribution; Urea - adverse effects; Urea - analogs & derivatives; Urea - pharmacokinetics; Urea - therapeutic use; Molecular imaging; PSMA; Fluorine-18; Prostate cancer; PET

Purpose Prostate-specific membrane antigen (PSMA) is a recognized target for imaging prostate cancer. Here we present initial safety, biodistribution, and radiation dosimetry results with [ 18 F]DCFPyL, a second-generation fluorine-18-labeled small-molecule PSMA inhibitor, in patients with prostate...